Posted October 20, 2018 09:18:00Nexgen is a drug discovery company that has been in business for over 10 years.
They were founded in 2013 by entrepreneur Sam Kalinowski.
They now have about 30,000 employees worldwide and have raised more than $5.5 billion from private investors.
Kalinowsers team is based in Palo Alto, California.
Nexgens flagship product is a biotechnology that uses DNA sequencing to detect drugs in the body, a technology that has helped the company generate more than 1,000 patents in the last decade.
NeXgen has recently launched its own product, a product that uses a DNA-based test to detect certain bacteria that can cause diarrhea, pneumonia, and other illnesses.
Nexi, the company’s product is being tested by a number of hospitals in the United States and Canada.
Nexia is a synthetic version of the DNA sequencing technology, NeXgens DNA-sequencing technology, that can be used to detect specific bacteria in the intestines.
This new product is similar to the DNA sequencer in Nexgins DNA sequencers, and is being developed by a different company.
The company also recently announced that it will be expanding its product to include blood tests that are more accurate than those already available in hospitals.
NeXi, Nexgi and NeXhi are now listed on Nasdaq under the ticker symbol NEX.
Nexta is a pharmaceutical company based in Taiwan that specializes in the development and commercialization of biologics and drug delivery systems.
It was founded in 2012.
Nexta was recently acquired by a Taiwanese drugmaker and has been operating under the brand NeXTALAY.
NeXTALay, Nextai and Nexti are now traded on Nasexxta under the symbol NXT.